Kobayashi M, Yamaguchi A, Imai T, Otake H, Igarashi H, Hatori N, Tomiyoshi K, Inoue T, Endo K, Sakahara H
Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi.
Kaku Igaku. 1993 Apr;30(4):441-7.
We performed basic and clinical studies of IRMA "BL-CA195" kit in which monoclonal antibody CC3C195 was used as 125I-labeled tracer and solid phase antibody. The reproducibility of the assay results and dilution curves were satisfactory. There was a close correlation between serum CA195 and CA19-9 values, and many patients with pancreatic and colorectal cancer had elevated serum CA195 concentrations. Unlabeled CC3C195 antibody dose-dependently and completely inhibited the binding of 125I-labeled anti-CA19-9 antibody to its corresponding antigen. These findings suggest that CA195 and CA19-9 share common antigenic determinants.
我们使用单克隆抗体CC3C195作为125I标记示踪剂和固相抗体,对IRMA“BL-CA195”试剂盒进行了基础和临床研究。检测结果和稀释曲线的重复性令人满意。血清CA195与CA19-9值之间存在密切相关性,许多胰腺癌和结直肠癌患者血清CA195浓度升高。未标记的CC3C195抗体以剂量依赖方式完全抑制125I标记的抗CA19-9抗体与其相应抗原的结合。这些发现表明CA195和CA19-9具有共同的抗原决定簇。